Status:
COMPLETED
Conditioning Regimens for Patients With Severe Aplastic Anemia Transplanted With Marrow From an Unrelated Donor
Lead Sponsor:
Fred Hutchinson Cancer Center
Collaborating Sponsors:
University of Minnesota
University of California, Los Angeles
Conditions:
Anemia, Aplastic
Eligibility:
All Genders
Up to 55 years
Phase:
PHASE1
PHASE2
Brief Summary
A single arm dose optimization study in which all patients are given a fixed dose of Cytoxan (4 x 50 mg/kg) plus ATG (3 x 30 mg/kg) and the TBI dose starting at 3 x 200 cGy is escalated or de-escalate...
Eligibility Criteria
Inclusion
- Life-threatening marrow failure of nonmalignant etiology;
- failure to respond to the best available immunosuppressive treatment;
- lack of a HLA-identical family member
Exclusion
- Severe disease other than aplastic anemia that would severly limit the probability of survival during the graft procedure;
- HIV seropositive patients;
- clonal abnormalities or myelodysplastic syndrome;
Key Trial Info
Start Date :
May 1 1993
Trial Type :
INTERVENTIONAL
End Date :
July 1 2007
Estimated Enrollment :
85 Patients enrolled
Trial Details
Trial ID
NCT00144729
Start Date
May 1 1993
End Date
July 1 2007
Last Update
April 30 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance
Seattle, Washington, United States, 98109